In support of the Delta and BCRF partnership, we have designed a special uniform polo that Delta employees can purchase and wear during October 2023. 100% of all Pink Boutique sales will fund critical research. In addition, if you spend more than $50, shipping is free! Together, we are Carrying Us Closer to a Cure!

Above Wing Wear Guidelines HereBelow Wing Wear Guidelines HereHoliday Wear Guidelines HereTop Wear Guidelines Here


Since 2005, Delta employees, customers and their friends and families have raised over $24 million for BCRF, including last year's efforts of $3 million. The collective contributions have funded the vital work of 99 different research projects over the years in the pursuit of eradicating breast cancer. ​ Despite the devastating impacts of COVID-19, we remain committed to our values of giving back and supporting each other and the communities where we live, work and serve. Below are some great resources and information to keep you informed about BCRF and the research projects we support. 


About the Breast Cancer Research Foundation (BCRF)

Breast cancer is a complex disease with no simple solution. Research is the key to stopping it in its tracks. Founded in 1993, the Breast Cancer Research Foundation is the largest private funder of breast cancer research in the world. Join us in fueling the world’s most promising research. With you, we will be the end of breast cancer. Learn more and get involved at BCRF.org.


Breast cancer is a complex disease with no simple solution. Research is the key to stopping it in its tracks. Founded in 1993, the Breast Cancer Research Foundation is the largest private funder of breast cancer research in the world. BCRF invests in the best minds in science—from those investigating prevention to metastasis. BCRF's approach accelerates the entire field and moves us closer to the answers we urgently need. We can’t stop now. Join us in fueling the world’s most promising research. With you, we will be the end of breast cancer.

Breast Cancer Research Foundation's Immunotherapy Initiative

Immunotherapy is one of the most exciting areas in breast cancer research. See how BCRF-supported researchers are moving this field forward with innovative approaches such as cryoablation. Learn more and get involved at BCRF.org.

Why Research is the Reason to Support BCRF

Research is the only way to change how this generation and the next experiences breast cancer. That's why it's the Breast Cancer Research Foundation's sole focus all year long. We're giving a voice to this community, through research. Because #ResearchIsTheReason they have a story to tell.

But after the challenges of the past year, funding for cancer research is at risk. We can’t let the pandemic undermine what we’ve accomplished, threaten future progress, and cost us still more lives. Join us in fueling the world’s most promising research with BCRF.


Abenaa Brewster, MD, MHS

Professor, Department of Clinical Cancer Prevention
Director, Nellie B. Connally Breast Center The University of Texas MD Anderson Cancer Center
Houston, TX

Goal: Developing a new, blood-based screening tool for detecting breast cancer.

Impact: Dr. Brewster and her team developed a new technology to detect exosomes, which are small particles secreted by cancer cells. This technique could provide a sensitive, easily accessible, and noninvasive method for the early detection of breast cancer and provide guidance on the frequency of other types of screening.

What’s next: The team will conduct a study to rigorously evaluate the performance and reliability of this technology by detecting exosomes in the blood of women one to two years before their breast cancer diagnosis. The team will also assess perceptions and preferences for this form of screening from a cohort of women at high risk of developing breast cancer. The findings could translate into increased rates of screening, earlier detection, and decreased mortality associated with breast cancer.

Jack Cuzick, PhD

John Snow Professor of Epidemiology
Director, Wolfson Institute of Preventive Medicine
Head, Centre for Cancer Prevention
Queen Mary University of London
London, United Kingdom

Prudence Francis, MBBS,B Med Sc, FRACP, MD

Associate Professor
Head of Medical Oncology, Breast Service
University of Melbourne
Melbourne, Australia

Goal: Predicting breast cancer risk and enhancing our understanding of preventive therapy.

Impact: Analysis of biobanked samples—blood, tissue, and clinical data from consenting patients—is critical for cancer research. Mountains of data can be gleaned from biobanks, and Drs. Francis, Cuzick, and their teams are pioneers in leveragingthe biobanked data to expand our understanding of breast cancer prevention. Their studies may assist with the development of personalized treatments.

What’s next: Prevention research is a long-term game as it takes many years of follow-up to ensure that preventive measures are effective. In the coming year, the team will continue to add digitized data from ongoing, imminent clinical trials to their databank to further explore correlative factors including patient hormone levels and prognostic biological indicators using new artificial intelligence-based technologies.

Mary L. (Nora) Disis, MD

Helen B. Slonaker Endowed Professor for Cancer Research
Associate Dean for Translational Health Sciences
University of Washington School of Medicine
Fred Hutchinson Cancer Research Center
Seattle, WA

Goal: Developing vaccines to lower the risk of developing breast cancer

Impact: Obesity is an important risk factor for breast cancer. An early event that leads to increased breast cancer risk is the development of inflammatory T-cell infiltration into fat. This inflammation results in significant metabolic imbalances that lead to cancer. Dr. Disis and her team created an anti-inflammatory vaccine (ADVac) targeting proteins highly expressed in inflammatory fat.

What’s next: The team will conduct a study in laboratory models to determine the extent ADVac immunization can reverse metabolic dysfunction at the tumor and prevent cancer development. They will also collect data that will help quickly identify where ADVac-specific T- cells go in the body after vaccination and if beneficial changes in inflammation patterns are observed in other organs. The addition ofthe drug metformin will also be tested for improved vaccine efficacy and prevention of tumor development.

Stanislav Emelianov, PhD

Joseph M. Pettit Endowed Chair
Georgia Research Alliance Eminent Scholar
Professor of Electrical & Computer Engineering and Biomedical Engineering
Georgia Institute of TechnologyEmory School of Medicine
Atlanta, Georgia

Goal: Improving immunotherapy in breast cancer.

Impact: Cellular immunotherapies, which cultivate a patient’s own immune cells so that they recognize and target tumors, are highly effective in blood cancers but less effective in “solid” cancers like breast cancer. The primary challenge in breast cancer is that cellular immunotherapies fail to penetrate the tumor, which prevents them from working effectively.

What’s next: Dr. Emelianov and his team successfully devised a novel strategy to safely deliver immune cells directly to tumors. In the coming year, the team will continue to improve immune cell delivery and infiltration to tumor tissue and test their method for its efficacy in eliciting a robust immune response. Their results may provide a way to customize and improve immunotherapy, predict outcomes, and plan a better treatment.

Luca Gianni, MD

President, Gianni Bonadonna Foundation
Fondazione Michelangelo ONLUS
Milan, Italy

Goal: To improve response to immunotherapy in triple-negative breast cancer (TNBC).

Impact: A clinical trial tested the combination of immunotherapy with chemotherapy in TNBC and was recently extended to high- risk HER2-positive breast cancer. Dr. Gianni’s team analyzes samples from these trials to understand the mechanism of immune resistance and sensitivity to develop better immunotherapy strategies. They have discovered that unique interactions between specific types of immune and tumor cells in these patients might inform who benefits most from immunotherapy.

What’s next: The team will continue to analyze the complexmolecularandgeneticdatagleanedfromthese important trials to discover relevant and predictive biological indicators that indicate which patients would benefit from these types of immunotherapies.

Sofia D. Merajver, MD, PhD

Professor of Internal Medicine and Epidemiology
Director, Breast and Ovarian Cancer Risk Evaluation Program
University of Michigan
Ann Arbor, Michigan

Goal: To identify new strategies for the prevention and treatment of aggressive breast cancers.

Impact: Dr. Merajver studies inflammatory (IBC) and triple-negative breast cancers (TNBC), breast cancers that often spread to other vital organs. She and her team are studying the networks these cancer cells form when they spread and are developing new avenues to attack these cells as they are spreading by interfering withtheirmobilitythroughoutthebodyandtheenergytheyneed to survive.

What’s next: Dr. Merajver’s team is aiming to identify and exploit metabolic vulnerabilities of cancer cells and develop unique laboratory models and devices, which closely mimic environments where cancer cells spread. These novel systems and devices will allow the team to develop better drug screening methods, model the activity of drugs in a more realistic environment, and allow for better therapeutic options for patients with aggressive breast cancer.

Gad Rennert, MD, PhD

Director, Clalit National Israeli Cancer Control Center
Professor and Chairman,Department of Community Medicine
Carmel Medical Center
Haifa, Israel

Goal: To understand the origins of breast cancer.

Impact: The underlying cause of most breast cancers is unknown. Continuous funding from BCRF enabled Dr. Rennert and his team to develop one of the largest breast cancer studies in the world, incorporating 30,000-plus individuals—of Israeli and Arab descent—with and without breast cancer. This study now has20 years worth of data that inform health habits and risk factors and trends in breast cancer incidence and mortality. Biological samples from this study, collected and analyzed over time, now benefit from new analytical technologies such as artificial intelligence and are subjected to retroactive tests to develop new insights.

What’s next: In the coming year, the team will continue to study women who developed cancer early (before age 45). They will continue to build a comprehensive dataset with individualized information on genetic mutations and biological drivers that may increase breast cancer risk.

Liewei Wang, MD, PhD

Chair of Pharmacology, Department of Molecular
Pharmacology and Experimental Therapeutics
Professor of Pharmacology
Director of Pharmacogenomics Translational Program,
Center for Individualized Medicine
Mayo Clinic Medical School
Rochester, Minnesota

James N. Ingle, MD, FASCO

Professor of Oncology
Mayo Clinic College of Medicine
Mayo Clinic Cancer Center
Rochester, Minnesota

Goal: Identifying genetic markers that can help select the optimal endocrine therapy for individual patients with hormone receptor- positive breast cancer.

Impact: While endocrine therapy has proven effective in many patients with estrogen receptor-positive breast cancers (affecting ~1M per year globally), some do not respond as well or experience such intolerable side effects that they suspend therapy. The research team is studying the mechanisms by which a patient’s individual genetic makeup can affect tolerance and response to endocrine therapy.

What’s next: The team is extending its approaches to include state of the art techniques to identify genes and their functions associated with disease progression and response to endocrine therapy, such as aromatase inhibitors (AIs).They will build on the biomarkers they have already identified to further understand the mechanism of AI-resistant estrogen receptor positive breast cancer.

Justin Balko, PharmD, PhD

Ingram Associate Professor for Cancer Research
Associate Professor of Medicine and Pathology, Microbiology & Immunology
Co-Leader Breast Cancer Research Program
Vanderbilt Ingram Cancer Center
Vanderbilt University Medical Center
Nashville, Tennessee

Goal: Developing methods to identify which patients would benefit from immunotherapy.

Impact: Immunotherapy helps a patient’s own immune system fight cancer and can be very effective, but only in about 15 percent of patients with triple-negative breast cancer (TNBC). The use of immunotherapy drugs is complicated by their potentially life-long side effects including those similar to autoimmune disorders. Dr. Balko and his team have identified a test that may help identifywhich patients do or do not need immunotherapy so that these side-effects could be avoided.

What’s next: Dr. Balko's team will analyze tumor tissuefrom patients enrolled in an ongoing clinical trial to determine the efficacy of their test and optimize its use. This may provide anew way to identify patients that will benefit from immunotherapy and lead to its testing in larger clinical trials. The data his team collects could alsopotentially reveal new effective treatments or biomarkers to improve outcomes for patients with aggressive TNBC.

Melissa B. Davis, PhD

Director, Institute of Genomic Medicine
Professor, Microbiology, Biochemistry and Immunology
Morehouse School of Medicine
Atlanta, Georgia

Goal: Identifying social and biological determinants of breast cancer outcomes in Black women.

Impact: Black women are 41 percent more likely to die from their breast cancer than white women. This is due, in part, to a lack of diversity in genomics research that propagates a paucity of equitable therapeutic/diagnostic options to serve a diverse population ofbreast cancer patients. Dr.Davis’team will study the relationshipsbetween ancestry, the tumor microenvironment, socialdeterminants of health, and breast cancer survival to address this disparity.

What’s next: Her team will utilizepatient samples from a cohort of 100 patients with breast cancer from the African diaspora. They will focus on the immune cells within the tumor microenvironment and assess how they influence tumor response. Her team will also examine how social determinants of health such as obesity, diet, and psychosocial health may influence the tumor microenvironment to alter immune responses. These analyses in concert with patient outcomes data will help identify how multiple factors can influence breast cancer disparities.

Alana Welm, PhD

Professor, Department of Oncological Sciences
Senior Director of Basic Science
Ralph E. and Willia T. Main Presidential Endowed Chair in Cancer Research
University of Utah Health
Salt Lake City, Utah

Goal: Developing a new strategy to improve the efficacy of immunotherapy in metastatic breast cancer (MBC).

Impact: Researchers are focused on harnessing the power of the immune system to eliminate breast cancer. Dr. Welm has found a promising novel target for immunotherapy and key mediator of breast cancer metastasis--sfRON. This target influences the host immune system not the tumor itself and allows the tumor cells to escape immune surveillance and metastasize. Dr. Welm found that blocking sfRON prevented metastasis and is now deciphering the mechanism of action.

What’s next: Dr. Welm showed that sfRONincreases specific immune cells around tumors and is testingexisting RON inhibitors in combination with immunotherapy to block the process. Her team will leverage laboratory models they created to mimic the metastatic tumor environment to study the effects of RON inhibitors. She hopes the results will warrant moving this combination strategy into the clinic to treat MBC.

Mylin A. Torres, MD

Professor, Department of Radiation Oncology
Co-Leader, Cancer Prevention and Control Research Program
Emory University School of Medicine
Atlanta, Georgia

Goal: Identifying genetic determinants of treatment-related comorbidities in Black patients with early-stage breast cancer

Impact: Non-Hispanic Black (NHB) women are two times more likely to die after a breast cancer diagnosis than non-Hispanic white (NHW) women in metropolitan Atlanta. Following treatment, other illnesses are observed more frequently in NHB than NHW women and contribute to poor survival. These illnesses are classified as treatment-emergent comorbidities. Polygenic risk scores (PRS) are a composite of genetic variants within an individual’s DNA that may indicate a level of risk for developing a disease.

What’s next: The team will conduct a study of NHB and NHW women with early stage, HR-positive/HER2-negative breast cancer. Patients will undergo testing to assess genetic differences that might be associated with treatment-related comorbidities. Identifying genetic predictors of these comorbidities will enable physicians to personalize care, support proactive preventative interventions, and select treatments that are more effective, less toxic, and improve overall survival.